miR-29C is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 10, 2013, Pages 1274-1282

  Fang, Yi ^a   Yu, Xiaofang ^a   Liu, Yong ^b   Kriegel, Alison J ^b   Heng, Yanyan ^a   Xu, Xialian ^a   Liang, Mingyu ^b   Ding, Xiaoqiang ^a  

^a FUDAN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Collagen type II 1; HIF; miR 29C; Tropomyosin 1 ; Tubulointerstitial fibrosis

Indexed keywords

ALPHA TROPOMYOSIN; COBALT CHLORIDE; COLLAGEN TYPE 2; COLLAGEN TYPE 2 ALPHA1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MICRORNA 29; MICRORNA 29C; MIMOSINE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY CORTEX; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; UPREGULATION;

EID: 84878641501     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00287.2012     Document Type: Article

References (58)

1. Bakin AV, Safina A, Rinehart C, Daroqui C, Darbary H, Helfman DM. A critical role of tropomyosins in TGF-beta regulation of the actin cytoskeleton and cell motility in epithelial cells. Mol Biol Cell 15: 4682-4694, 2004.
2. Bhatt K, Mi QS, Dong Z. microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles. Am J Physiol Renal Physiol 300: F602-F610, 2011.
3. Cao CC, Ding XQ, Ou ZL, Liu CF, Li P, Wang L, Zhu CF. In vivo transfection of NF-kappaB decoy oligodeoxynucleotides attenuate renal ischemia/reperfusion injury in rats. Kidney Int 65: 834-845, 2004.
4. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50, 2008.
5. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 75: 1145-1152, 2009.
6. Coutu P, Bennett CN, Favre EG, Day SM, Metzger JM. Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked alpha-tropomyosin mutations. Circ Res 94: 1235-1241, 2004.
7. Cooper JA. Actin dynamics: tropomyosin provides stability. Curr Biol 12: R523, 2002.
8. Couzin J. Breakthrough of the year: small RNAs make big splash. Science 298: 2296-2297, 2002.
9. Couzin J. MicroRNAs make big impression in disease after disease. Science 319: 1782-1784, 2008.
10. Grande MT, López-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 5: 319-328, 2009.
11. Haase VH. Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 291: F271-F281, 2006.
12. Hill P, Shukla D, Tran MG, Aragones J, Cook HT, Carmeliet P, Maxwell PH. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 19: 39-46, 2008.
13. Houle F, Poirier A, Dumaresq J, Huot J. DAP kinase mediates the phosphorylation of tropomyosin-1 downstream of the ERK pathway, which regulates the formation of stress fibers in response to oxidative stress. J Cell Sci 120: 3666-3677, 2007.
14. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, Ji Y, Zhao C, Wang J, Yang BB, Zhang Y. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE 1: e116, 2006.
15. Imbeaud S, Graudens E, Boulanger V, Barlet X, Zaborski P, Eveno E, Mueller O, Schroeder A, Auffray C. Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces. Nucleic Acids Res 33: e56, 2005.
16. Jiang SH, Chen Y, Zou JZ, Xu X, Zhang X, Liu C, Fang Y, Ding X. Diverse effects of ischemic pretreatments on the long-term renal damage induced by ischemia-reperfusion. Am J Nephrol 30: 440-449, 2009.
17. Ju H, Hao J, Zhao S, Dixon IM. Antiproliferative and antifibrotic effects of mimosine on adult cardiac fibroblasts. Biochim Biophys Acta 1448: 51-60, 1998.
18. Kairaitis LK, Wang Y, Gassmann M, Tay YC, Harris DC. HIF-1a expression follows microvascular loss in advanced murine adriamycin nephrosis. Am J Physiol Renal Physiol 288: F198-F206, 2005.
19. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784, 2003.
20. Kato M, Arce L, Natarajan R. MicroRNAs and their role in progressive kidney diseases. Clin J Am Soc Nephrol 4: 1255-1266, 2009.
21. Kriegel AJ, Fang Y, Liu Y, Tian Z, Mladinov D, Matus IR, Ding X, Greene AS, Liang M. MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor beta 1: a novel role of miR-382. Nucleic Acids Res 38: 8338-8347, 2010.
22. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 44: 237-244, 2012.
23. Li N, Yi F, Sundy CM, Chen L, Hilliker ML, Donley DK, Muldoon DB, Li PL. Expression and actions of HIF prolyl-4-hydroxylase in the rat kidneys. Am J Physiol Renal Physiol 292: F207-F216, 2007.
24. Liang M, Liu Y, Mladinov D, Cowley AW Jr, Trivedi H, Fang Y, Xu X, Ding X, Tian Z. MicroRNA: a new frontier in kidney and blood pressure research. Am J Physiol Renal Physiol 297: F553-F558, 2009.
25. Liang M. MicroRNA: a new entrance to the broad paradigm of systems molecular medicine. Physiol Genomics 8: 113-115, 2009.
26. Liang M. Pathway knowledge base as a tool for systems molecular medicine (perspectives). Physiol Genomics 30: 209-212, 2007.
27. Liu Y, Taylor NE, Lu L, Usa K, Cowley AW Jr, Ferreri NR, Yeo NC, Liang M. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension 55: 974-982, 2010.
28. Lorenzen JM, Haller H, Thum T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 7: 286-294, 2011.
29. Makeyev EV, Maniatis T. Multilevel regulation of gene expression by microRNAs. Science 319: 1789-1790, 2008.
30. Maric C, Sandberg K, Hinojosa-Laborde C. Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat. J Am Soc Nephrol 15: 1546-1556, 2004.
31. Maurer B, Stanczyk J, Jüngel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, Gay S, Distler O. McroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 62: 1733-1743, 2010.
32. Maxwell PH. Hypoxia-inducible factor as a physiological regulator. Exp Physiol 90: 791-797, 2005.
33. Meister G. miRNAs get an early start on translational silencing. Cell 131: 25-28, 2007.
34. Mölleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M, Friedman SL, Tornøe I, Schlosser A, Klöppel G, Schmiegel W, Meyer HE, Holmskov U, Stühler K. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology 49: 1257-1266, 2009.
35. Morita T, Mayanagi T, Sobue K. Dual roles of myocardin-related transcription factors in epithelial mesenchymal transition via slug induction and actin remodeling. J Cell Bio 179: 1027-1042, 2007.
36. Nangaku M. Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Nephron Exp Nephrol 98: e8-e12, 2004.
37. Otogawa K, Ogawa T, Shiga R, Ikeda K, Kawada N. Induction of tropomyosin during hepatic stellate cell activation and the progression of liver fibrosis. Hepatol Int 3: 378-383, 2009.
38. Pittenger MF, Kazzaz JA, Helfman DM. Functional properties of non-muscle tropomyosin isoforms. Curr Opin Cell Biol 6: 96-104, 1994.
39. Qin W, Chung AC, Huang XR, Meng XM, Hui DS, Yu CM, Sung JJ, Lan HY. TGF-fj/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 22: 1462-1474, 2011.
40. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F, Trautwein C, Luedde T. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53: 209-218, 2011.
41. Rosenberger C, Khamaisi M, Abassi Z, Shilo V, Weksler-Zangen S, Goldfarb M, Shina A, Zibertrest F, Eckardt KU, Rosen S, Heyman SN. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int 73: 34-42, 2008.
42. Saito T, Sumithran E, Glasgow EF, Atkins RC. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 32: 691-699, 1987.
43. Satoh S, Yamaguchi T, Hitomi A, Sato N, Shiraiwa K, Ikegaki I, Asano T, Shimokawa H. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol 455: 169-174, 2002.
44. Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu MR, O'neill GM, Yang N, Verrills NM, Kavallaris M, Gunning PW. Tissue-specific tropomyosin isoform composition. J Histochem Cytochem 53: 557-570, 2005.
45. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Lightfoot S, Menzel W, Granzow M, Ragg T. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7: 3, 2006.
46. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, Chen CJ, Hildesheim A, Sugden B, Ahlquist P. MicroRNA 29c is down-regulated in nasopharyn-geal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 105: 5874-5878, 2008.
47. Tanaka T, Nangaku M. The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 alpha in progression of chronic kidney disease. Curr Opin Nephrol Hypertens 19: 43-50, 2010.
48. Tian Z, Greene AS, Usa K, Matus IR, Bauwens J, Pietrusz JL, Cowley AW Jr, Liang M. Renal regional proteomes in young Dahl salt-sensitive rats. Hypertension 51: 899-904, 2008.
49. Tian Z, Liu Y, Usa K, Mladinov D, Fang Y, Ding X, Greene AS, Cowley AW Jr, Liang M. A novel role of fumarate metabolism in Dahl salt-sensitive hypertension. Hypertension 54: 255-260, 2009.
50. Tian Z, Greene AS, Pietrusz JL, Matus IR, Liang M. microRNA-target pairs in rat kidneys identified through microRNA microarray, proteomic, and bioinformatic analysis. Genome Res 18: 404-411, 2008.
51. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105: 13027-13032, 2008.
52. Varga AE, Stourman NV, Zheng Q, Safina AF, Quan L, Li X, Sossey-Alaoui K, Bakin AV. Silencing of the tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta. Onco-gene 24: 5043-5052, 2005.
53. Xu X, Kriegel AJ, Liu Y, Usa K, Mladinov D, Liu H, Fang Y, Ding X, Liang M. Delayed ischemic preconditioning contributes to renal protection by upregulation of miR-21. Kidney Int 82: 1167-1175, 2012.
54. Ye Y, Hu Z, Lin Y, Zhang C, Perez-Polo JR. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res 87: 535-544, 2010.
55. Yoshioka T, Shiraga H, Yoshida Y, Fogo A, Glick AD, Deen WM, Hoyer JR, Ichikawa I. "Intact nephrons" as the primary origin of proteinuria in chronic renal disease. Study in the rat model of subtotal nephrectomy. J Clin Invest 82: 1614-23, 1988.
56. Yu X, Fang Y, Ding X, Liu H, Zhu J, Zou J, Xu X, Zhong Y. Transient hypoxia-inducible factor activation in rat renal ablation and reduced fibrosis with L-mimosine. Nephrology (Carlton) 17: 58-67, 2012.
57. Yu X, Fang Y, Liu H, Zhu J, Zou J, Xu X, Jiang S, Ding X. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration. Nephrol Dial Transplant 27: 3110-3119, 2012.
58. Zheng Q, Safina A, Bakin AV. Role of high-molecular weight tropo-myosins in TGF-beta-mediated control of cell motility. Int J Cancer 122: 78-90, 2008.